Kamada (NASDAQ:KMDA) Issues Earnings Results, Beats Estimates By $0.05 EPS

Kamada (NASDAQ:KMDA) posted its earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05, FiscalAI reports. Kamada had a net margin of 11.60% and a return on equity of 8.41%. The firm had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million.

Here are the key takeaways from Kamada’s conference call:

• Record first-half performance: Revenue rose 13% year over year to $100.2 million, adjusted EBITDA increased 14% to $25.7 million, and net income grew 18% to $13.4 million. Second-quarter revenue and EBITDA also reached company records, with a 26% EBITDA margin.
• Kamada reiterated its 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, noting that first-half results are approximately 50% of the annual midpoint and that it remains comfortable with second-half expectations.
• The company signed a three-year, $50 million normal-source plasma supply agreement, with initial commercial sales expected in the fourth quarter of 2026. Houston and San Antonio facilities are expected to provide roughly $16 million–$20 million of annual capacity, while specialty plasma will support Kamada’s own products.
• Management reported continued demand growth for KEDRAB, VARIZIG, HepaGam B and other commercial products, alongside expansion of its biosimilar distribution business in Israel and the MENA region. Kamada expects its biosimilar portfolio to generate $15 million–$20 million in annual sales within several years.
• CFO Chaime Orlev will leave the company at the end of 2026 after nine years, and Kamada has begun searching for a successor, creating a near-term executive-transition risk.

Kamada Trading Up 3.3%

Shares of KMDA stock traded up $0.24 on Friday, hitting $7.50. 29,410 shares of the stock were exchanged, compared to its average volume of 61,430. The firm has a market capitalization of $431.32 million, a PE ratio of 19.72, a P/E/G ratio of 0.63 and a beta of 0.86. Kamada has a one year low of $6.50 and a one year high of $9.35. The firm’s 50 day moving average is $7.22 and its two-hundred day moving average is $7.96.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KMDA. Barclays PLC boosted its holdings in shares of Kamada by 417.1% in the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 3,862 shares during the period. XTX Topco Ltd bought a new position in Kamada in the 4th quarter worth about $103,000. SIH Partners LLLP purchased a new position in Kamada during the 4th quarter valued at about $134,000. Quadrature Capital Ltd lifted its holdings in shares of Kamada by 53.5% in the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after buying an additional 7,627 shares in the last quarter. Finally, Man Group plc purchased a new position in Kamada during the third quarter valued at approximately $199,000. 20.38% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KMDA shares. William Blair set a $15.00 target price on Kamada in a research report on Tuesday, July 21st. Benchmark reissued a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Wall Street Zen cut Kamada from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings downgraded shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $13.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.